Actively Recruiting
Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors Agonists
Led by University Hospital, Geneva · Updated on 2026-04-01
38
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how semaglutide, a medication used for type 2 diabetes, affects the time food stays in the stomach and its implications for anesthesia management. The study focuses on determining the optimal time to stop this medication before surgery to ensure the stomach is empty. This observational research is conducted at the Geneva University Hospitals and involves 38 participants with type 2 diabetes treated with GLP-1 receptor agonists. Participants will take part in a 7-day study period during which they will visit the hospital three times for gastric ultrasounds. On each visit day, participants will eat a breakfast that includes bread, cereals, or proteins between 7 and 8 am, then fast for 6 hours from solid food and 2 hours from liquids before the ultrasound. Smokers must abstain from smoking for 12 hours before the exam. An anesthesiologist will perform the gastric ultrasound at 2 pm to evaluate the gastric volume. During the study, participants will undergo ultrasound assessments to measure stomach content after fasting periods. Researchers will monitor gastric volume to understand safe fasting times for anesthesia in diabetic patients treated with GLP-1 analogs. The study aims to provide information about gastric emptying 7 days after the last medication injection. Participation involves hospital visits for tests, and the study is approved by the relevant ethics committee and follows international guidelines.
CONDITIONS
Brief Title
Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female or male aged 18 years or older
- Diagnosed with type 2 diabetes
- Treated with GLP-1 analog for more than 3 months
- Signed informed consent
- ASA physical status classification between I and IV
You will not qualify if you...
- Currently treated with insulin
- Have gastrointestinal motility disorders
- History of gastric surgery
- Presence of hiatal hernia
- Recent trauma
- Unable to lie down for the exam
- Unable to follow exam instructions due to language barrier or dementia
- Body mass index (BMI) greater than 40
- Unable to stop smoking 12 hours before measurements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 week
Participants undergo gastric ultrasonography to assess gastric emptying after fasting and treatment with GLP-1 receptor agonists.
1 visit (in-person) 7 days after the last injection
Trial Site Locations
Total: 1 location
1
Hôpitaux Universitaires de Genève
Geneva, Canton of Geneva, Switzerland, 1211
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here